Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

This phase 1 study sought to characterize the safety, tolerability, and pharmacokinetic behavior of VLX1570, a small molecule inhibitor of the deubiquitinases (DUBs) that remove sterically bulky ubiquitin chains from proteins during processing in the19S regulatory subunit of the proteasome, in patie...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Invest New Drugs
Autori principali: Rowinsky, Eric K., Paner, Agne, Berdeja, Jesus G., Paba-Prada, Claudia, Venugopal, Parameswaran, Porkka, Kimmo, Gullbo, Joachim, Linder, Stig, Loskog, Angelica, Richardson, Paul G., Landgren, Ola
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer US 2020
Soggetti:
Phase I Studies
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7497669/
https://ncbi.nlm.nih.gov/pubmed/32125598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-00915-4
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi